Clinical data mining reveals analgesic effects of lapatinib in cancer patients

Abstract Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a promising target for a next generation of anti-inflammatory drugs that are not expected to have the side effects of currently available anti-inflammatory drugs. Lapatinib, an FDA-approved drug for cancer treatment, has rece...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuo Zhou, Fang Zheng, Chang-Guo Zhan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8c08fbabe69a47deb6bc50024576c91f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c08fbabe69a47deb6bc50024576c91f
record_format	dspace
spelling	oai:doaj.org-article:8c08fbabe69a47deb6bc50024576c91f2021-12-02T12:09:51ZClinical data mining reveals analgesic effects of lapatinib in cancer patients10.1038/s41598-021-82318-w2045-2322https://doaj.org/article/8c08fbabe69a47deb6bc50024576c91f2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82318-whttps://doaj.org/toc/2045-2322Abstract Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a promising target for a next generation of anti-inflammatory drugs that are not expected to have the side effects of currently available anti-inflammatory drugs. Lapatinib, an FDA-approved drug for cancer treatment, has recently been identified as an mPGES-1 inhibitor. But the efficacy of lapatinib as an analgesic remains to be evaluated. In the present clinical data mining (CDM) study, we have collected and analyzed all lapatinib-related clinical data retrieved from clinicaltrials.gov. Our CDM utilized a meta-analysis protocol, but the clinical data analyzed were not limited to the primary and secondary outcomes of clinical trials, unlike conventional meta-analyses. All the pain-related data were used to determine the numbers and odd ratios (ORs) of various forms of pain in cancer patients with lapatinib treatment. The ORs, 95% confidence intervals, and P values for the differences in pain were calculated and the heterogeneous data across the trials were evaluated. For all forms of pain analyzed, the patients received lapatinib treatment have a reduced occurrence (OR 0.79; CI 0.70–0.89; P = 0.0002 for the overall effect). According to our CDM results, available clinical data for 12,765 patients enrolled in 20 randomized clinical trials indicate that lapatinib therapy is associated with a significant reduction in various forms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients. Our CDM results have demonstrated the significant analgesic effects of lapatinib, suggesting that lapatinib may be repurposed as a novel type of analgesic.Shuo ZhouFang ZhengChang-Guo ZhanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shuo Zhou Fang Zheng Chang-Guo Zhan Clinical data mining reveals analgesic effects of lapatinib in cancer patients
description	Abstract Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a promising target for a next generation of anti-inflammatory drugs that are not expected to have the side effects of currently available anti-inflammatory drugs. Lapatinib, an FDA-approved drug for cancer treatment, has recently been identified as an mPGES-1 inhibitor. But the efficacy of lapatinib as an analgesic remains to be evaluated. In the present clinical data mining (CDM) study, we have collected and analyzed all lapatinib-related clinical data retrieved from clinicaltrials.gov. Our CDM utilized a meta-analysis protocol, but the clinical data analyzed were not limited to the primary and secondary outcomes of clinical trials, unlike conventional meta-analyses. All the pain-related data were used to determine the numbers and odd ratios (ORs) of various forms of pain in cancer patients with lapatinib treatment. The ORs, 95% confidence intervals, and P values for the differences in pain were calculated and the heterogeneous data across the trials were evaluated. For all forms of pain analyzed, the patients received lapatinib treatment have a reduced occurrence (OR 0.79; CI 0.70–0.89; P = 0.0002 for the overall effect). According to our CDM results, available clinical data for 12,765 patients enrolled in 20 randomized clinical trials indicate that lapatinib therapy is associated with a significant reduction in various forms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients. Our CDM results have demonstrated the significant analgesic effects of lapatinib, suggesting that lapatinib may be repurposed as a novel type of analgesic.
format	article
author	Shuo Zhou Fang Zheng Chang-Guo Zhan
author_facet	Shuo Zhou Fang Zheng Chang-Guo Zhan
author_sort	Shuo Zhou
title	Clinical data mining reveals analgesic effects of lapatinib in cancer patients
title_short	Clinical data mining reveals analgesic effects of lapatinib in cancer patients
title_full	Clinical data mining reveals analgesic effects of lapatinib in cancer patients
title_fullStr	Clinical data mining reveals analgesic effects of lapatinib in cancer patients
title_full_unstemmed	Clinical data mining reveals analgesic effects of lapatinib in cancer patients
title_sort	clinical data mining reveals analgesic effects of lapatinib in cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8c08fbabe69a47deb6bc50024576c91f
work_keys_str_mv	AT shuozhou clinicaldataminingrevealsanalgesiceffectsoflapatinibincancerpatients AT fangzheng clinicaldataminingrevealsanalgesiceffectsoflapatinibincancerpatients AT changguozhan clinicaldataminingrevealsanalgesiceffectsoflapatinibincancerpatients
_version_	1718394640772628480

Clinical data mining reveals analgesic effects of lapatinib in cancer patients

Ejemplares similares